This Biotech Has a Tech Company’s DNA

Most biotechs burn cash, but this one’s turning heads with its 34.8x return on invested capital and PE ratio of 18.6x – well below industry average.


Buy This, Not That: Intel’s Pain Is This Stock’s Gain

As semiconductor giants circle Intel’s assets, one emerges as the clear winner for investors – but it’s not the obvious choice.


3 Signs It’s Time to Sell Your Small-Cap Stocks

Knowing when to sell is just as important as when to buy. Use trends, volume, and sentiment to lock in profits before it’s too late.


The Real Driver of Stock Market Gains in 2025

U.S. productivity is growing at record rates, and new policies could accelerate this trend. Here’s how to position yourself…


Can Analysts Predict Stock Moves Before They Happen?

From Uber’s recent surge to the science behind ratings, here’s what you need to know about market forecasts.


Dealmaker’s Diary: Why This $1.5B Stock Buyback Matters

Beyond the headlines about a major hedge fund stake, this tech giant’s metrics suggest significant upside ahead.


Buy This, Not That: Super Bowl’s Big Winners (It’s Not Who You Think)

The real competition wasn’t on the field – it was during commercial breaks. Here’s what these epic ads tell us about two major stocks.


Why This Market Shrugs Off Tariff Drama

New tariffs, same bull market – what 2018 teaches us about today’s trade tensions.


Market Check: Why I’m Not Worried (Yet)

Markets remain inches from record highs despite recent weakness. While the Magnificent Seven show concerning divergence, we haven’t seen a 5% correction since fall.


How to Profit From Trump’s Tariff Playbook

Trump’s unique approach to tariffs is creating predictable market swings. Here’s how traders and investors can capitalize on this new pattern of volatility…


BROUGHT TO YOU BY MANWARD PRESS